Showing results (61-70 of 175) with videos related to

Sort By:
Pageof 18
Scientific Reports|February 2, 2018
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinibKiichiro Ninomiya, Kadoaki Ohashi, Go Makimoto, et al.
Journal of Cancer Research and Clinical Oncology|March 29, 2021
Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitorsNaofumi Hara, Eiki Ichihara, Daijiro Harada, et al.
Experimental Cell Research|September 23, 2024
A novel molecular target, superoxide dismutase 1, in ALK inhibitor-resistant lung cancer cells, detected through proteomic analysisNoriko Miyake, Nobuaki Ochi, Masami Takeyama, et al.
Cancer Science|May 26, 2021
Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan StudyHidehito Horinouchi, Naoyuki Nogami, Hideo Saka, et al.
JCO Precision Oncology|September 19, 2024
Response to Imatinib in a Patient With Gastric Adenocarcinoma With <i>KIT</i> Q556_K558 In-Frame Deletion: A Case ReportKiichiro Ninomiya, Daisuke Ennishi, Kunio Okamoto, et al.
Japanese Journal of Clinical Oncology|October 21, 2025
Remarkable response of gastric adenocarcinoma with FGFR2-TRIM44 fusion to pemigatinib: a case reportMiho Fujiwara, Kiichiro Ninomiya, Emi Chikuie, et al.
Biochemical and Biophysical Research Communications|November 5, 2017
Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutationsTomoki Tamura, Yuka Kato, Kadoaki Ohashi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2019
The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancerEiki Ichihara, Daijiro Harada, Koji Inoue, et al.
Japanese Journal of Clinical Oncology|October 2, 2013
Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002Katsuyuki Hotta, Nagio Takigawa, Akiko Hisamoto-Sato, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2014
Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experienceYuka Kato, Katsuyuki Hotta, Nagio Takigawa, et al.
Pageof 18